JP2013504589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504589A5 JP2013504589A5 JP2012528909A JP2012528909A JP2013504589A5 JP 2013504589 A5 JP2013504589 A5 JP 2013504589A5 JP 2012528909 A JP2012528909 A JP 2012528909A JP 2012528909 A JP2012528909 A JP 2012528909A JP 2013504589 A5 JP2013504589 A5 JP 2013504589A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- actriib
- composition
- fusion protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 70
- 102000037865 fusion proteins Human genes 0.000 claims description 70
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 40
- 125000000539 amino acid group Chemical group 0.000 claims description 27
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims description 23
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 230000008468 bone growth Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 230000037182 bone density Effects 0.000 claims description 4
- 230000037118 bone strength Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 125000003473 lipid group Chemical group 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000037257 muscle growth Effects 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 229940122361 Bisphosphonate Drugs 0.000 claims description 2
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102000008108 Osteoprotegerin Human genes 0.000 claims description 2
- 108010035042 Osteoprotegerin Proteins 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 230000001195 anabolic effect Effects 0.000 claims description 2
- 150000004663 bisphosphonates Chemical group 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 59
- 230000002354 daily effect Effects 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 53
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27628709P | 2009-09-09 | 2009-09-09 | |
| US61/276,287 | 2009-09-09 | ||
| PCT/US2010/048322 WO2011031901A1 (en) | 2009-09-09 | 2010-09-09 | Actriib antagonists and dosing and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015027521A Division JP2015108012A (ja) | 2009-09-09 | 2015-02-16 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504589A JP2013504589A (ja) | 2013-02-07 |
| JP2013504589A5 true JP2013504589A5 (OSRAM) | 2013-10-24 |
| JP6211767B2 JP6211767B2 (ja) | 2017-10-11 |
Family
ID=43732801
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528909A Active JP6211767B2 (ja) | 2009-09-09 | 2010-09-09 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2015027521A Withdrawn JP2015108012A (ja) | 2009-09-09 | 2015-02-16 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2016232363A Withdrawn JP2017048243A (ja) | 2009-09-09 | 2016-11-30 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2017193336A Withdrawn JP2018002730A (ja) | 2009-09-09 | 2017-10-03 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2018227174A Withdrawn JP2019055977A (ja) | 2009-09-09 | 2018-12-04 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2020105837A Pending JP2020146070A (ja) | 2009-09-09 | 2020-06-19 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015027521A Withdrawn JP2015108012A (ja) | 2009-09-09 | 2015-02-16 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2016232363A Withdrawn JP2017048243A (ja) | 2009-09-09 | 2016-11-30 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2017193336A Withdrawn JP2018002730A (ja) | 2009-09-09 | 2017-10-03 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2018227174A Withdrawn JP2019055977A (ja) | 2009-09-09 | 2018-12-04 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| JP2020105837A Pending JP2020146070A (ja) | 2009-09-09 | 2020-06-19 | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20110070233A1 (OSRAM) |
| EP (3) | EP3202459B1 (OSRAM) |
| JP (6) | JP6211767B2 (OSRAM) |
| KR (4) | KR20120062874A (OSRAM) |
| CN (1) | CN102781518A (OSRAM) |
| AU (4) | AU2010292203A1 (OSRAM) |
| BR (1) | BR112012005225B8 (OSRAM) |
| CA (1) | CA2773494A1 (OSRAM) |
| ES (2) | ES2869580T3 (OSRAM) |
| IL (1) | IL218502A0 (OSRAM) |
| IN (1) | IN2012DN02766A (OSRAM) |
| MX (2) | MX385217B (OSRAM) |
| WO (1) | WO2011031901A1 (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3059245B1 (en) | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| MX2008006626A (es) | 2005-11-23 | 2008-09-24 | Acceleron Pharma Inc | Antagonistas de activin-actriia y usos para promover el crecimiento de huesos. |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| WO2008094708A2 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI606062B (zh) | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| CA2729096C (en) * | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| HRP20191109T1 (hr) | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010083034A1 (en) * | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| EP3260130B1 (en) * | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| JP2014502260A (ja) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ， インコーポレイテッド | Ａｃｔｒｉｉａ結合剤およびその使用 |
| EP2793925B1 (en) | 2011-12-19 | 2019-03-20 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
| ES2715710T3 (es) | 2013-01-25 | 2019-06-05 | Shire Human Genetic Therapies | Folistatina en el tratamiento de la distrofía muscular de Duchenne |
| US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| EP3985024A1 (en) | 2013-02-01 | 2022-04-20 | Atara Biotherapeutics, Inc. | Anti-activin-a compounds for the treatment of ovarian cancer |
| KR102077286B1 (ko) * | 2014-06-04 | 2020-02-13 | 악셀레론 파마 인코포레이티드 | 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| AU2015358469B2 (en) | 2014-12-03 | 2021-05-27 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for treating anemia |
| CN107636154A (zh) | 2015-03-26 | 2018-01-26 | 阿塞勒隆制药公司 | 促滤泡素抑制素相关的融合蛋白及其用途 |
| SG10201913747PA (en) | 2015-04-22 | 2020-03-30 | Biogen Ma Inc | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| TWI814187B (zh) * | 2015-05-13 | 2023-09-01 | 美商西建公司 | 使用ACTRII配位體捕捉以治療β-地中海型貧血 |
| JP2018522579A (ja) | 2015-05-20 | 2018-08-16 | セルジーン コーポレイション | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| US20170240639A1 (en) * | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
| PL3426680T3 (pl) | 2016-03-10 | 2025-03-31 | Acceleron Pharma Inc. | Białka wiążące receptor aktywiny typu 2 i ich zastosowania |
| WO2017192847A1 (en) * | 2016-05-04 | 2017-11-09 | University Of Cincinnati | Female fertility therapies |
| CN110036025B (zh) * | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JP7258021B2 (ja) | 2017-11-09 | 2023-04-14 | ケロス セラピューティクス インコーポレイテッド | アクチビンＩＩａ型受容体変異体を含む医薬組成物 |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| CN112601538B (zh) | 2018-05-09 | 2025-08-19 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| MX2023005565A (es) * | 2020-11-11 | 2024-02-23 | Hq Han | Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos. |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US20050186593A1 (en) * | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6287816B1 (en) * | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| US6692925B1 (en) * | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| WO1994015965A1 (en) * | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Growth differentiation factor-3 |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5831050A (en) * | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5658876A (en) * | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
| US5760010A (en) * | 1995-01-01 | 1998-06-02 | Klein; Ira | Method of treating liver disorders with a macrolide antibiotic |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| DE69636866D1 (en) | 1995-04-11 | 2007-03-15 | Gen Hospital Corp | Reverse "two-hybrid"-systeme |
| US6132988A (en) * | 1995-10-27 | 2000-10-17 | Takeda Chemical Industries, Ltd. | DNA encoding a neuronal cell-specific receptor protein |
| US6605699B1 (en) * | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| CA2297489A1 (en) | 1997-07-30 | 1999-02-11 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| WO1999010364A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| US6696411B1 (en) * | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU765584B2 (en) * | 1998-09-17 | 2003-09-25 | Eli Lilly And Company | Protein formulations |
| US6548634B1 (en) * | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
| US6777205B1 (en) * | 1998-11-06 | 2004-08-17 | Sterrenbeld Biotechnologie North America, Inc. | Host cells expressing recombinant human erythropoietin |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| JP4487376B2 (ja) * | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| US6627424B1 (en) * | 2000-05-26 | 2003-09-30 | Mj Bioworks, Inc. | Nucleic acid modifying enzymes |
| US6632180B1 (en) * | 2000-09-07 | 2003-10-14 | John H. Laragh | Method for evaluating and treating hypertension |
| DE10045591A1 (de) * | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| WO2002032925A2 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US20040132675A1 (en) * | 2002-02-08 | 2004-07-08 | Calvin Kuo | Method for treating cancer and increasing hematocrit levels |
| DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
| US20040071659A1 (en) | 2001-04-30 | 2004-04-15 | Betty Chang | Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| US6855344B2 (en) * | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| US20030144203A1 (en) * | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| US6998118B2 (en) * | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| AU2003217612A1 (en) * | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
| WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2002953327A0 (en) * | 2002-12-12 | 2003-01-09 | Monash University | Methods of diagnosing prognosing and treating activin associated diseases and conditions |
| US20040197828A1 (en) * | 2003-03-26 | 2004-10-07 | Gaddy Dana P. | Method for diagnosis and treatment of bone turnover |
| WO2005028517A2 (en) * | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| KR20060026860A (ko) * | 2003-06-02 | 2006-03-24 | 와이어쓰 | 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도 |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| US20050197292A1 (en) * | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| EP3059245B1 (en) * | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Actrii receptor antagonistic antibodies |
| CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| MX2008006626A (es) * | 2005-11-23 | 2008-09-24 | Acceleron Pharma Inc | Antagonistas de activin-actriia y usos para promover el crecimiento de huesos. |
| JP4822562B2 (ja) * | 2006-01-20 | 2011-11-24 | ベックマン コールター， インコーポレイテッド | 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法 |
| WO2007120767A2 (en) * | 2006-04-14 | 2007-10-25 | Amgen Inc. | Agonist erythropoietin receptor antibodies |
| AU2007249827A1 (en) * | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| CN104095838A (zh) * | 2006-07-21 | 2014-10-15 | 莱因实验室公司 | 醋酸钙的液体组合物 |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| PL2124999T3 (pl) * | 2006-12-18 | 2013-03-29 | Acceleron Pharma Inc | Antagoniści aktywiny-actrii i zastosowania do leczenia niedokrwistości |
| WO2008094708A2 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| TWI606062B (zh) * | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| CA2685306A1 (en) * | 2007-06-01 | 2008-12-11 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| WO2009038745A1 (en) * | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| CA2729096C (en) * | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| HRP20191109T1 (hr) * | 2008-08-14 | 2019-09-20 | Acceleron Pharma Inc. | Gdf klopke za uporabu u liječenju anemije |
| WO2010083034A1 (en) * | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| SG174273A1 (en) * | 2009-04-27 | 2011-10-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
| AU2010258931B2 (en) * | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
| CN107267520A (zh) * | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| EP3260130B1 (en) * | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| CA2781152A1 (en) * | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| EA202090053A3 (ru) * | 2011-10-17 | 2020-06-30 | Акселерон Фарма, Инк. | Способы и композиции для лечения неэффективного эритропоэза |
| CA2874117C (en) * | 2012-07-02 | 2021-10-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia |
-
2010
- 2010-09-09 ES ES16195379T patent/ES2869580T3/es active Active
- 2010-09-09 JP JP2012528909A patent/JP6211767B2/ja active Active
- 2010-09-09 ES ES10816109.2T patent/ES2613523T3/es active Active
- 2010-09-09 EP EP16195379.9A patent/EP3202459B1/en active Active
- 2010-09-09 BR BR112012005225A patent/BR112012005225B8/pt active IP Right Grant
- 2010-09-09 CA CA2773494A patent/CA2773494A1/en not_active Abandoned
- 2010-09-09 IN IN2766DEN2012 patent/IN2012DN02766A/en unknown
- 2010-09-09 KR KR1020127008733A patent/KR20120062874A/ko not_active Ceased
- 2010-09-09 MX MX2019006655A patent/MX385217B/es unknown
- 2010-09-09 AU AU2010292203A patent/AU2010292203A1/en not_active Abandoned
- 2010-09-09 EP EP21167747.1A patent/EP3919068A1/en not_active Withdrawn
- 2010-09-09 KR KR1020217006733A patent/KR20210029836A/ko not_active Ceased
- 2010-09-09 CN CN2010800516176A patent/CN102781518A/zh active Pending
- 2010-09-09 EP EP10816109.2A patent/EP2475427B1/en active Active
- 2010-09-09 KR KR1020207019417A patent/KR20200086378A/ko not_active Ceased
- 2010-09-09 MX MX2012003005A patent/MX340451B/es active IP Right Grant
- 2010-09-09 US US12/878,988 patent/US20110070233A1/en not_active Abandoned
- 2010-09-09 WO PCT/US2010/048322 patent/WO2011031901A1/en not_active Ceased
- 2010-09-09 KR KR1020197011941A patent/KR102133683B1/ko active Active
-
2012
- 2012-03-06 IL IL218502A patent/IL218502A0/en unknown
-
2015
- 2015-02-16 JP JP2015027521A patent/JP2015108012A/ja not_active Withdrawn
-
2016
- 2016-03-17 AU AU2016201712A patent/AU2016201712B2/en active Active
- 2016-11-30 JP JP2016232363A patent/JP2017048243A/ja not_active Withdrawn
-
2017
- 2017-10-03 JP JP2017193336A patent/JP2018002730A/ja not_active Withdrawn
- 2017-11-13 US US15/810,581 patent/US20180194828A1/en not_active Abandoned
-
2018
- 2018-01-19 AU AU2018200463A patent/AU2018200463B2/en active Active
- 2018-12-04 JP JP2018227174A patent/JP2019055977A/ja not_active Withdrawn
-
2020
- 2020-05-27 US US16/884,564 patent/US20210115105A1/en not_active Abandoned
- 2020-06-19 JP JP2020105837A patent/JP2020146070A/ja active Pending
- 2020-06-23 AU AU2020204176A patent/AU2020204176A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504589A5 (OSRAM) | ||
| JP2010518006A5 (OSRAM) | ||
| JP2010518079A5 (OSRAM) | ||
| JP2013127002A5 (OSRAM) | ||
| AU2010305281B2 (en) | Siglec 15 antibodies in treating bone loss-related disease | |
| CN101668421B (zh) | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 | |
| ES2389697T3 (es) | Variantes de desintegrina y usos farmacéuticos de los mismos | |
| Saylor et al. | New and emerging therapies for bone metastases in genitourinary cancers | |
| KR20090071598A (ko) | 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료 | |
| ES2734886T3 (es) | Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral | |
| JP2012125259A5 (OSRAM) | ||
| KR20190098255A (ko) | 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도 | |
| Bhandari et al. | Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats | |
| RS66182B1 (sr) | Stabilne višedozne kompozicije koje sadrže antitelo i konzervans | |
| JP2011526626A5 (OSRAM) | ||
| EA021425B1 (ru) | Мутанты fgf21 и их применение | |
| CN101842101A (zh) | 水杨酰苯胺修饰的肽用作口服治疗剂 | |
| CN110114065A (zh) | 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生 | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| JP2010538005A5 (OSRAM) | ||
| JP2014500278A5 (OSRAM) | ||
| CA2761885A1 (en) | Methods and compositions for treating lupus | |
| US20140322332A1 (en) | Antagonists of muc1 | |
| Nagai et al. | Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs | |
| US8183201B2 (en) | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |